Compass Pathways (CMPS) announced yesterday morning with earnings that as a result of changing timelines for its Phase 3 trials, it will be reducing its workforce by approximately 30%, including eliminating some senior management positions, “to further focus the organization and its capital resources on successfully delivering the COMP360 program.” The company’s non-COMP360 preclinical efforts will be stopped and it is “exploring a potential externalization” for its digital health tools.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on CMPS:

• Compass Pathways price target lowered to $18 from $23 at RBC Capital

• Compass Pathways price target lowered to $12 from $22 at Maxim

• Compass Pathways Focuses on Key Psilocybin Program

• Microsoft reports Q1 beat, Comcast weighs cable networks spinoff: Morning Buzz

• Rising High: Compass Pathways reports Q3 earnings